small molecule

BRILINTA

TICAGRELOR

Loss of exclusivityJuly 2036latest FDA-listed patent expiry
CompanyASTRAZENECA PHARMACEUTICALS LP

Drug detail

Brand nameBRILINTA
Active ingredientTICAGRELOR
Strength60MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalSeptember 2015
Marketing statusRX

Listed patents

PatentExpiresType
10300065*PEDJuly 2036
10300065January 2036use U-2542
8425934*PEDOctober 2030
8425934April 2030product

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

BRILINTA patent cliff — loss of exclusivity July 2036 | CliffBio